The Indian Glivec calculus: what changed for pharma after the hype
This article was originally published in SRA
Hyperbolists think that the decision of the Indian Supreme Court to reject Novartis' Glivec (imatinib mesylate) patent claim has changed the face of the pharma market in India and perhaps in other emerging pharma nations, too1. But calmer calculus makes it clear that everything is not quite that dramatic.
You may also be interested in...
The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the oncology drug while the originator's patent stands valid.
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”